diseas
outbreak
caus
middl
east
respiratori
syndrom
coronaviru
merscov
still
ongo
middl
east
peopl
infect
sinc
first
report
septemb
despit
great
effort
licens
vaccin
therapeut
merscov
remain
unavail
merscov
spike
protein
import
viral
antigen
known
mediat
hostreceptor
bind
viru
entri
well
induc
robust
humor
cellmedi
respons
human
infect
review
highlight
import
protein
merscov
life
cycl
summar
recent
advanc
develop
vaccin
therapeut
base
protein
discuss
strategi
explor
develop
new
medic
countermeasur
merscov
coronavirus
cov
spheric
envelop
virus
larg
unseg
singl
posit
rna
genom
kb
length
twothird
genom
end
translat
two
overlap
polyprotein
later
cleav
pro
pl
pro
yield
nonstructur
protein
nsp
remain
onethird
genom
respons
code
structur
protein
spike
glycoprotein
small
envelop
protein
e
integr
membran
protein
genomeassoci
nucleocapsid
protein
n
cov
also
contain
hemagglutinin
esteras
interspers
gene
coronaviru
genom
sever
gene
code
accessori
protein
although
dispens
viru
growth
vitro
determin
use
revers
genet
target
mutagenesi
analys
involv
regul
host
immun
system
narayanan
et
al
niemey
et
al
yang
et
al
protein
e
n
mainli
respons
assembl
virion
protein
involv
receptor
bind
bear
membran
fusion
capabl
cov
infect
saif
thu
protein
essenti
role
viru
entri
determin
tissu
cell
tropism
well
host
rang
cov
infect
avian
mammalian
speci
schmidt
et
al
exampl
infecti
bronchiti
viru
ibv
infect
chicken
porcin
epidem
diarrhea
viru
pedv
porcin
respiratori
coronaviru
prcv
transmiss
gastroenter
viru
tgev
infect
pig
bovin
coronaviru
bcov
infect
bovin
felin
infecti
periton
viru
fipv
infect
cat
canin
coronaviru
ccov
infect
dog
virus
result
signific
econom
loss
anim
industri
worldwid
commonli
veterinari
cov
infect
prevent
either
modifi
live
inactiv
cov
vaccin
carmichael
cavanagh
hick
et
al
olsen
welter
et
al
attenu
live
virus
bcov
tgev
ibv
temperaturesensit
mutant
fipv
usual
administ
oral
intranas
induc
activ
mucos
immun
contrast
inactiv
vaccin
administ
parenter
adjuv
avail
induc
activ
passiv
immun
bcov
tgev
ccov
ibv
cov
also
caus
diseas
human
fig
two
human
coronavirus
human
isol
volunt
common
cold
unit
salisburi
unit
kingdom
almeida
tyrrel
hamr
procknow
hendley
et
al
mcintosh
et
al
tyrrel
byno
human
isol
child
suffer
bronchiol
conjunct
netherland
van
der
hoek
et
al
follow
year
anoth
cov
human
identifi
patient
pneumonia
hong
kong
woo
et
al
human
coronavirus
mainli
caus
subclin
mild
infect
account
common
cold
heikkinen
jarvinen
howev
sever
lower
respiratori
tractrel
case
report
infant
elderli
falsey
et
al
mcintosh
et
al
noksokoivisto
et
al
pene
et
al
vabret
et
al
human
coronavirus
also
lifethreaten
pandem
potenti
sever
acut
respiratori
syndrom
coronaviru
sarscov
caus
infect
relat
death
worldwid
decad
later
epidem
outbreak
middl
east
respiratori
syndrom
mer
remind
us
possibl
anoth
potenti
pandem
scale
sar
first
case
report
kingdom
saudi
arabia
ksa
septemb
bermingham
et
al
zaki
et
al
sinc
merscov
ie
etiolog
agent
behind
mer
de
groot
et
al
spread
countri
total
laboratoryconfirm
infect
relat
death
case
fatal
rate
major
human
case
report
middl
east
like
due
presenc
dromedari
camel
confirm
carri
live
merscov
potenti
sourc
human
infect
azhar
et
al
memish
et
al
howev
whether
dromedari
camel
intermediari
host
origin
reservoir
remain
open
present
may
merscov
spread
south
korea
via
travel
middl
east
caus
sever
infect
cluster
result
total
confirm
case
evid
viru
superspread
hospit
clinic
one
subsequ
patient
travel
china
fell
ill
mark
first
instanc
import
merscov
case
spread
directli
middl
east
su
et
al
event
remind
past
geograph
barrier
diseas
easili
bypass
due
increasingli
global
natur
world
unlik
sarscov
great
diseas
control
effort
chines
govern
suddenli
disappear
number
mer
case
still
rise
reinforc
urgent
need
develop
vaccin
specif
drug
target
cov
especi
antiepidem
merscov
measur
although
year
pass
sinc
initi
outbreak
present
still
avail
antisar
drug
market
nonetheless
mani
antivir
agent
identifi
summar
sever
excel
review
adedeji
sarafiano
keum
jeong
kumar
et
al
liang
ramajayam
et
al
yang
et
al
sarscov
virus
liang
lu
et
al
yang
et
al
proteas
pro
pro
papainlik
proteas
pl
pro
merscov
respons
process
huge
polyprotein
matur
nsp
baezsanto
et
al
kilianski
et
al
yang
et
al
deem
viabl
target
inhibitor
screen
small
molecul
ester
target
merscov
pro
pl
pro
shown
efficaci
inhibit
merscov
replic
vitro
chan
et
al
cheng
et
al
kilianski
et
al
though
activ
cytotox
need
assess
vivo
addit
exist
drug
screen
identifi
potenti
inhibitor
sever
demonstr
clinic
relev
mild
advers
effect
low
halfmaxim
effect
concentr
ec
among
ribavirin
interferona
display
effect
vitro
chan
et
al
de
wild
et
al
merscov
infect
rhesu
macaqu
mild
diseas
benefit
mer
patient
obviou
fortun
lopinavirritonavir
shown
improv
outcom
merscovinfect
common
marmoset
repres
sever
manifest
mer
patient
demonstr
potenti
clinic
use
recent
mirna
sirna
target
merscov
also
predict
util
seri
bioinformat
tool
nur
et
al
evalu
vivo
vitro
requir
clinic
trial
may
begin
review
first
describ
chemic
structur
featur
protein
summar
current
publish
vaccin
therapeut
research
merscov
base
protein
highlight
suitabl
protein
target
design
medic
countermeasur
merscov
merscov
genom
assembl
similar
cov
gene
code
locat
onethird
genom
end
fig
type
trimer
transmembran
protein
locat
surfac
viral
envelop
give
rise
spikeshap
protrus
virion
amino
acid
length
heavili
glycosyl
predict
nlink
glycosyl
site
consist
larg
ectodomain
short
cytosol
tail
fig
protein
cov
divid
two
function
subunit
xia
et
al
ntermin
subunit
form
globular
head
membraneembed
ctermin
region
form
stalk
region
involv
receptor
recognit
bind
less
conserv
compar
stalk
two
discret
independ
fold
domain
locat
nand
ctermini
abl
bind
receptor
merscov
util
ctermin
domain
residu
receptor
bind
domain
rbd
du
et
al
lu
et
al
mou
et
al
wang
et
al
specif
mersrbd
divid
two
part
core
subdomain
extern
subdomain
although
share
low
amino
acid
sequenc
ident
core
subdomain
structur
sarsrbd
mersrbd
superimpos
well
li
et
al
indic
conserv
core
structur
among
cov
contrast
extern
subdomain
structur
two
protein
differ
greatli
interestingli
extern
subdomain
mainli
involv
receptor
bind
thu
result
differ
receptor
usag
cov
mersrbd
four
antiparallel
bstrand
compris
extern
region
bind
blade
iv
v
bpropel
human
also
known
dipeptidyl
peptidas
iv
receptor
merscov
fig
accordingli
block
bind
mersrbd
prevent
viru
attach
inhibit
viru
infect
intriguingli
mersrbd
stimul
product
robust
antibodi
mice
rabbit
neutral
viru
infect
et
al
mou
et
al
suggest
protein
may
repres
promis
immunogen
elicit
neutral
antibodi
nab
addit
receptor
recognit
bind
proteolysi
anoth
critic
determin
cov
tropism
pathogenesi
millet
whittak
simmon
et
al
similarli
merss
protein
cleav
differ
host
proteas
previous
thoroughli
review
worth
note
merscov
use
twostep
furin
cleavag
activ
process
infect
cell
specif
first
cleav
biosynthesi
posit
merscov
enter
target
cell
cleav
posit
adjac
fusion
peptid
within
design
millet
whittak
import
first
cleavag
confirm
analysi
bat
coronaviru
abl
bind
unabl
infect
cell
due
lack
first
proteolyt
conserv
motif
recogn
furin
introduct
furin
recognit
site
treatment
pseudotyp
particl
trypsin
confer
particl
abil
infect
cell
likewis
inhibit
proteolysi
furin
inhibitor
decreas
merscov
infect
suscept
cell
concentrationdepend
manner
millet
whittak
indic
cleavag
critic
viru
entri
viral
fusion
protein
group
three
class
class
fusion
protein
repres
influenza
hemagglutinin
trimer
singlechain
precursor
prime
cleavag
trimer
precursor
form
sixhelix
bundl
class
ii
fusion
protein
repres
flaviviru
prme
protein
icosahedr
symmetr
assembl
dimer
virion
prime
cleavag
heterodimer
partner
protein
form
homotrim
membran
fusion
class
iii
fusion
protein
complic
includ
one
sever
protein
undergo
obviou
prime
event
earp
et
al
gao
harrison
kielian
rey
melikyan
white
et
al
cov
protein
typic
class
fusion
protein
recent
cryoelectron
microscopi
structur
mhv
protein
report
kirchdoerf
et
al
wall
et
al
structur
reveal
overal
prefus
architectur
full
length
ectodomain
fig
g
show
ntermin
domain
ntd
ctermin
domain
ctd
present
v
shape
therefor
contribut
overal
triangular
appear
trimer
fig
h
subunit
connect
viral
membran
character
presenc
long
ahelic
fig
h
structur
inform
serv
foundat
structurebas
design
bcov
vaccin
immunogen
bind
fusion
merscov
envelop
host
cell
membran
occur
mediat
subunit
belouzard
et
al
class
fusion
protein
merscov
contain
multipl
key
compon
includ
fusion
peptid
conserv
heptad
repeat
hr
fig
howev
unlik
extens
studi
sarscov
fusion
peptid
littl
experiment
investig
undertaken
concern
merscov
though
similar
concentr
hydrophob
residu
identifi
equival
region
merss
contrast
hr
contain
heptad
repeat
heptad
repeat
viru
well
studi
consist
typic
class
fusion
protein
hr
merscov
assembl
canon
sixhelix
bundl
call
fusion
core
three
helic
form
central
coiledcoil
core
three
chain
surround
core
side
groov
fig
believ
fusion
core
repres
postfus
state
part
envelop
structur
although
assum
locat
distal
one
anoth
prefus
state
seri
conform
chang
occur
envelop
structur
bind
receptor
result
bind
fusion
peptid
locat
nterminu
cell
membran
shortliv
intermedi
state
bend
bind
move
viru
membran
cell
membran
close
proxim
enabl
membran
fusion
process
intermedi
state
hr
expos
inhibitor
block
format
fusion
core
maintain
hr
intermedi
state
use
drug
inhibit
merscov
infect
role
receptor
bind
membran
fusion
make
perfect
target
vaccin
antivir
develop
previou
studi
sarscov
reveal
vaccin
base
protein
induc
antibodi
block
viru
bind
fusion
neutral
viru
infect
du
et
al
although
licens
mer
vaccin
avail
research
work
develop
potenti
vaccin
base
protein
sever
previou
review
touch
topic
papaneri
et
al
zhang
et
al
focu
recent
progress
vaccin
show
efficaci
mice
nonhuman
primat
nhp
andor
dromedari
includ
replicationdefici
viru
vector
dna
vaccin
subunit
vaccin
summar
tabl
mva
highli
attenu
vaccinia
viru
strain
lost
vaccinia
genom
replicationdefect
mammalian
cell
ura
et
al
previous
safe
administ
individu
vaccin
smallpox
ura
et
al
current
mvabas
vaccin
sever
diseasescondit
undergo
clinic
trial
includ
hepat
influenza
malaria
tuberculosi
cancer
gilbert
similar
approach
adopt
develop
vaccin
merscov
song
et
al
show
mice
intramuscularli
immun
plaqueform
unit
pfu
recombin
mvamerss
twice
within
interv
elicit
nab
song
et
al
volz
et
al
dissect
immunogen
vaccin
mice
volz
et
al
agreement
data
obtain
mva
use
smallpox
vaccin
immun
subcutan
intramuscular
rout
induc
equival
humor
cellular
immun
mice
addit
intramuscular
vaccin
evok
equal
amount
merssspecif
cell
across
low
pfu
high
pfu
dose
challeng
merscov
vaccin
mice
exhibit
littl
viru
replic
irrespect
rout
dose
use
volz
et
al
indic
efficaci
mvamerss
mous
model
recent
studi
haagman
et
al
reveal
vaccin
significantli
reduc
merscov
shed
dromedari
camel
haagman
et
al
four
dromedari
inocul
twice
fourweek
interv
pfu
mvsmerss
administ
nostril
pfu
mvamerss
deliv
intramuscularli
neck
addit
system
humor
cellular
immun
evok
vaccin
low
level
merscov
nab
viru
neutral
titer
detect
week
boost
immun
nostril
challeng
median
tissu
cultur
infecti
dose
tcid
viru
via
intranas
rout
anim
show
mild
clinic
sign
significantli
reduc
mean
viral
titer
nasal
respiratori
tract
compar
control
anim
advantag
vaccin
compat
clinic
use
industrialscal
product
addit
vector
grown
chicken
embryo
fibroblast
cef
without
need
addit
animalderiv
compon
cultur
protein
synthes
upon
serial
amplif
low
multipl
infect
although
efficaci
mice
dromedari
clearli
shown
still
data
demonstr
protect
effect
mvamerss
nhp
model
import
human
applic
studi
high
dose
mva
vector
pfu
result
sever
advers
event
human
gilbert
thu
strict
evalu
need
perform
mvamerss
applic
human
addit
one
immun
dromedari
develop
undetect
nab
nostril
time
challeng
excret
low
level
infecti
viru
day
post
infect
dpi
viru
challeng
haagman
et
al
sequenc
spike
gene
infecti
viru
show
chang
rbd
region
exclud
possibl
escap
mutat
stress
vaccineinduc
antibodi
consequ
underli
mechan
result
failur
mvamerss
boost
immun
warrant
investig
venezuelan
equin
enceph
viru
veev
belong
famili
alphavirida
lundstrom
structur
protein
veev
replac
heterolog
protein
interest
result
recombin
rna
replicon
packag
vrp
use
cotransfect
helper
rna
lundstrom
due
lack
structur
protein
gene
replicon
replicationdefect
vrpbase
vaccin
prostat
cancer
test
phase
clinic
trial
slovin
et
al
wecker
et
al
toxic
associ
immun
astut
studi
zhao
et
al
gener
vaccin
candid
merscov
insert
gene
vrp
vrp
zhao
et
al
mice
first
immun
infecti
unit
iu
vrp
footpad
boost
dose
week
later
mice
afterward
transduc
pfu
infect
pfu
merscov
strain
day
post
infect
viral
load
transgen
mice
decreas
nearli
undetect
level
zhao
et
al
indic
efficaci
mous
model
howev
evalu
nhp
requir
human
applic
dna
vaccin
induc
protect
inject
genet
engin
dna
contain
target
antigen
gene
sever
dna
vaccin
approv
veterinari
use
red
weiner
current
dna
vaccin
approv
human
use
product
clinic
trial
target
varieti
diseas
includ
hiv
influenza
hepat
b
c
human
papillomaviru
hpv
cancer
ferraro
et
al
wang
et
al
first
report
develop
dna
vaccin
insert
codonoptim
strain
code
sequenc
mammalian
express
vector
sinc
use
hiv
dna
vaccin
proven
safe
mice
nhp
barouch
et
al
catanzaro
et
al
although
three
intramuscular
immun
threetofour
week
interv
plasmid
dna
follow
electropor
stimul
merssspecif
nab
mice
rhesu
macaqu
immunogen
effici
combin
plasmid
dna
protein
mice
nhp
develop
higher
titer
nab
immun
plasmid
dna
twice
within
threetofour
week
follow
protein
mix
adjuv
use
either
dna
vaccin
protein
alon
challeng
approxim
pfu
merscov
strain
nhp
immun
protein
experi
lower
peak
volum
pulmonari
diseas
protein
group
clear
pulmonari
infiltr
rapidli
indic
strategi
promis
approach
mer
vaccin
develop
anoth
independ
group
also
develop
dnabas
mer
vaccin
increas
immunogen
muthumani
et
al
optim
express
mammalian
express
plasmid
codon
rna
optim
well
addit
highli
effici
immunoglobulin
e
ige
signal
peptid
instead
ntermin
methionin
epenhanc
deliveri
three
time
twotofourweek
interv
optim
dna
vaccin
induc
potent
cellular
immun
antigenspecif
nab
mice
macaqu
camel
notabl
nhp
two
dose
mg
vs
mg
per
immun
assess
immunogen
group
develop
similar
humor
immun
three
immun
howev
highdos
group
produc
cellular
immun
lowdos
group
four
week
final
immun
tcid
merscov
appli
inocul
nhp
compar
control
anim
group
vaccin
rhesu
macaqu
exhibit
significantli
lower
viral
load
interestingli
four
nhp
immun
lower
dose
dna
vaccin
fail
demonstr
radiograph
evid
infiltr
time
point
wherea
half
anim
vaccin
higher
dose
show
evid
minor
infiltr
resolv
day
infect
whether
phenomenon
associ
vaccin
dose
need
ascertain
human
usag
moreov
vaccin
use
immun
dromedari
one
three
anim
fail
develop
robust
nab
point
need
research
veterinari
use
dna
vaccin
characterist
simplic
versatil
absenc
preexist
immun
vector
thu
use
repeatedli
spark
extens
studi
develop
howev
initi
trial
fail
effici
stimul
recipi
immun
respons
may
part
due
insuffici
exposur
antigen
ferraro
et
al
wang
et
al
muthumani
et
al
appli
differ
strategi
solv
problem
combin
two
strategi
dnasubunit
vaccin
regimen
would
stimul
robust
immunoreact
recipi
possibl
level
decreas
time
vaccin
would
save
time
cost
effort
merscov
reli
bind
rbd
region
receptor
initi
infect
block
interact
specul
abolish
viru
entri
therefor
rbd
main
immunogen
elicit
specif
nab
mersrbd
previous
shown
effici
induc
nab
mice
rabbit
du
et
al
du
et
al
et
al
mou
et
al
follow
subcutan
vaccin
mgmous
rbdfc
presenc
equal
volum
follow
two
boost
dose
immunogen
adjuv
threeweek
interv
mice
develop
system
humor
cellular
immun
merscov
ten
day
last
immun
mice
transduc
intranas
challeng
pfu
merscov
day
later
merscov
detect
lung
immun
mice
dpi
high
titer
viru
found
control
mice
indic
merscov
rbd
highli
effect
protect
mice
merscov
challeng
vaccin
also
test
immun
mice
rhesu
macaqu
effici
combin
protein
protect
nhp
viru
challeng
compar
type
vaccin
subunit
vaccin
defin
compon
produc
consist
importantli
vaccin
design
base
knowledg
viral
pathogenesi
contain
synthet
immunogen
fragment
pathogen
consequ
avoid
allergen
andor
reactogen
sequenc
consid
aforement
featur
subunit
vaccin
repres
attract
vaccin
candid
howev
compar
inactiv
liveattenu
vaccin
proteinbas
subunit
vaccin
still
exhibit
rel
low
immunogen
de
gregorio
et
al
naz
dabir
podda
del
giudic
may
improv
sever
strategi
addit
suitabl
adjuv
increas
vaccin
time
combin
type
vaccin
date
licens
antimerscov
therapeut
howev
sever
strategi
current
investig
identifi
variou
specif
antivir
target
includ
mersrbdtarget
nab
block
viral
attach
peptid
inhibitor
target
prevent
format
fusion
core
small
molecul
without
defin
mechan
larg
number
human
monoclon
antibodi
mab
human
mab
character
licens
number
diseas
carter
dimitrov
approv
respiratori
syncyti
viru
rsv
term
viral
infecti
diseas
shadman
wald
experiment
mab
therapi
develop
influenza
ebola
viru
current
undergo
clinic
trial
bossart
et
al
bossart
et
al
lingwood
et
al
mascola
hayn
qiu
et
al
zhu
et
al
sarscov
convalesc
sera
far
test
antibodi
target
rbd
region
thu
constitut
promis
target
design
mab
therapeut
outbreak
mer
intern
sever
acut
respiratori
emerg
infect
consortium
also
recommend
use
convalesc
sera
mer
treatment
thu
vast
effort
devot
identifi
nab
target
varieti
strategi
mous
hybridoma
wang
et
al
screen
librari
tang
et
al
isol
human
mice
pascal
et
al
focu
proven
effici
vivo
summar
tabl
recent
studi
two
mousederiv
nab
merscov
gener
mice
immun
mersrbd
nab
specif
bind
immunogen
submicromolar
bind
affin
competit
assay
reveal
two
nab
like
recogn
proxim
overlap
epitop
neutral
viru
interf
protein
bind
nab
human
circumv
advers
effect
associ
use
mab
foreign
origin
serum
sick
base
structur
bound
mersrbd
paratop
residu
preserv
remain
amino
acid
substitut
counterpart
human
immunoglobulin
result
exhibit
similar
bind
affin
neutral
activ
parent
mous
antibodi
thu
vivo
evalu
perform
control
mice
intranas
infect
pfu
merscov
viral
load
plateau
pfug
tissu
dpi
decreas
pfug
tissu
dpi
wherea
either
intraven
administr
mgmous
one
day
challeng
effici
decreas
viral
load
lung
transduc
mice
case
viral
load
decreas
approxim
two
order
magnitud
pfug
tissu
dpi
limit
detect
pfug
tissu
dpi
indic
abil
prophylaxi
therapi
antibodi
merscov
infect
veloimmun
mice
type
transgen
mice
includ
dna
encod
human
ig
heavi
k
lightchain
variabl
region
instead
correspond
mous
dna
leav
mous
constant
region
intact
murphi
et
al
valenzuela
et
al
antibodi
gener
mice
essenti
indistinguish
natur
occur
human
antibodi
hundr
thousand
dose
veloimmunederiv
antibodi
safe
administ
human
bruggemann
et
al
digiandomenico
sellman
economid
et
al
murphi
et
al
pascal
et
al
immun
veloimmun
mice
dna
encod
merss
recombin
purifi
mersrbd
pascal
et
al
two
fulli
human
antibodi
bind
mersrbd
block
interact
protein
potent
neutral
merscov
infect
vitro
identifi
specif
two
nab
crosscompet
bind
mersrbd
therefor
may
potenti
use
togeth
cocktail
reduc
occurr
viral
escap
mutant
vivo
efficaci
two
mab
also
assess
transgen
mous
model
gener
replac
mous
code
sequenc
human
counterpart
pascal
et
al
prophylaxi
test
low
high
dose
mab
intraperiton
inject
h
intranas
infect
pfu
merscov
nab
abl
significantli
decreas
merscovspecif
rna
level
lung
dpi
two
log
mgmous
dose
compar
isotyp
control
antibodi
strikingli
dose
reduc
viru
level
effici
dose
near
level
detect
assay
addit
also
exhibit
potenti
diseas
treatment
mab
administ
day
viru
challeng
viru
titer
lung
mice
signific
abat
greater
two
log
reduct
day
dpi
indic
preand
postexposur
efficaci
human
mab
vivo
asid
nab
gener
wildtyp
transgen
mice
human
nab
also
isol
screen
phagedisplay
igm
fab
librari
ying
et
al
use
mersrbd
antigen
ying
et
al
identifi
panel
nab
merscov
amongst
show
highest
affin
antigen
neutral
pseudotyp
live
merscov
neutral
mgml
respect
mgkg
mgkg
inject
intraven
new
zealand
white
rabbit
follow
intranas
infect
tcid
merscov
complet
protect
observ
contrast
rabbit
inject
control
antibodi
develop
pulmonari
diseas
character
mild
perivascular
houser
et
al
ying
et
al
kd
equilibrium
dissoci
constant
ic
inhibitori
concentr
peribronchiolar
inflamm
viral
titer
peak
dpi
viral
load
significantli
reduc
rabbit
administ
dose
rout
intraven
intranas
addit
evid
inflamm
viru
antigen
observ
rabbit
administ
although
complet
protect
rabbit
merscov
prophylact
set
postexposur
treatment
nab
lead
signific
reduct
viral
rna
titer
houser
et
al
although
mechan
nab
suggest
competit
bind
host
receptor
mersrbd
direct
evid
come
structur
nab
bind
ligand
sever
complex
structur
nab
bound
mersrbd
solv
recogn
epitop
well
defin
wang
et
al
ying
et
al
yu
et
al
overal
heavychain
variabl
domain
v
h
lightchain
variabl
domain
v
l
four
nab
involv
interact
albeit
v
h
contribut
total
bind
surfac
reciproc
major
element
mersrbd
recogn
four
nab
overlap
focus
interloop
loop
connect
helix
strand
also
involv
bind
superimposit
mabsmersrbd
structur
previous
report
structur
complex
pdb
code
lu
et
al
indic
three
mab
converg
almost
perpendicularli
recogn
larg
differ
surfac
patch
viral
ligand
howev
mab
use
similar
angl
approach
host
receptor
target
mersrbd
fig
close
proxim
lead
strong
steric
clash
one
hot
spot
ligand
respons
interact
carbohydr
moieti
receptor
indic
proteincarbohydr
interact
might
import
bind
viral
entri
merscov
support
observ
residu
suscept
speci
predict
glycosyl
addit
bind
affin
mutat
mersrbd
reduc
approxim
compar
wildtyp
footprint
four
mab
mersrbd
also
compar
character
interfac
residu
locat
within
distanc
bound
antibodi
receptor
though
recogn
differ
surfac
patch
viral
ligand
two
residu
overlap
five
footprint
henc
four
mab
may
interfer
interact
present
strong
steric
hindranc
compet
residu
therebi
neutral
merscov
infect
base
fusion
mechan
class
fusion
protein
solubl
peptid
display
strong
effect
fusioninhibit
potenti
deriv
region
approv
us
food
drug
administr
first
hiv
fusion
entri
inhibitor
treatment
hiv
infect
two
decad
ago
jiang
et
al
sinc
mani
viral
fusion
inhibitor
envelop
virus
class
membran
fusion
protein
develop
blacklow
et
al
lombardi
et
al
wang
et
al
watanab
et
al
yu
et
al
follow
notion
peptid
could
potent
inhibit
merscov
fusion
entri
design
initi
two
peptid
base
synthes
inhibitori
effect
test
pseudotyp
viru
system
peptid
correspond
fulllength
potent
inhibitor
viral
infect
truncat
peptid
similar
correl
length
peptid
antivir
activ
observ
peptid
class
envelop
virus
jiang
lin
ec
inhibit
merscov
infect
calcul
mm
lu
et
al
design
similar
peptid
inhibitor
ec
valu
rang
mm
depend
cell
line
lu
et
al
antibodi
ying
et
al
mark
yellow
magenta
blue
orang
respect
bottom
panel
eeh
indic
footprint
overlap
mersrbd
surfac
shown
cyan
indic
antibodi
residu
recogn
indic
antibodi
repres
manner
top
panel
overlap
interfac
residu
highlight
red
amino
acid
identitiesposit
label
use
assay
introduc
hydrophil
residu
increas
saltbridg
interact
one
mutant
show
signific
improv
stabil
solubl
antivir
activ
inhibitori
activ
merssmedi
cellcel
fusion
increas
approxim
vivo
studi
demonstr
intranas
administ
effect
protect
transgen
mice
merscov
infect
reduct
viral
titer
lung
protect
enhanc
combin
interferon
b
channappanavar
et
al
use
pseudoviru
bear
fulllength
protein
merscov
inhibit
assay
zhao
et
al
assess
sever
hiv
entri
inhibitor
activ
merscov
entri
among
anhydridemodifi
human
serum
albumin
hphsa
show
antivir
activ
compound
carri
net
neg
charg
predict
interact
posit
charg
residu
protein
merscov
virion
similar
inhibit
hiv
sarscov
hpv
entri
chu
et
al
debnath
et
al
li
et
al
lu
et
al
wang
et
al
compound
also
submicromolar
ic
rel
low
cytotox
cell
efficaci
cytotox
need
evalu
vivo
develop
suitabl
anim
model
merscov
critic
understand
pathogenesi
preclin
test
vaccin
therapeut
unfortun
commonli
use
laboratori
anim
speci
hamster
mice
ferret
suscept
merscov
van
doremalen
munster
variat
among
speci
nhp
initi
use
anim
model
test
efficaci
drug
subsequ
transgen
mice
gener
summar
although
mice
suscept
merscov
infect
three
mous
model
develop
first
modifi
adenoviru
express
administr
intranas
mice
lead
human
receptor
express
cell
lung
includ
neg
express
mous
zhao
et
al
infect
merscov
viru
detect
lung
clear
day
young
mice
day
old
mice
moder
weight
loss
observ
old
mice
viru
clearanc
delay
sever
strain
immunocompromis
mice
compar
wild
type
mice
infect
mice
develop
pneumonia
character
extens
inflammatori
cell
infiltr
may
recapitul
respiratori
diseas
observ
mild
moder
human
case
fatal
case
occasion
occur
kidney
diseas
accordingli
model
difficult
evalu
model
therapeut
second
model
transgen
mice
global
express
gener
microinject
two
independ
group
zhao
et
al
challeng
overwhelm
dose
merscov
transgen
mice
gener
agraw
et
al
develop
sever
pneumonia
lead
death
day
viral
rna
detect
mani
organ
includ
heart
spleen
intestin
liver
kidney
addit
infecti
viru
isol
lung
brain
howev
infect
lower
dose
viru
mous
model
exhibit
earli
persist
lung
infect
delay
occurr
brain
infect
persist
inflammatori
infiltr
seen
lung
brain
well
focal
infiltr
liver
patholog
seen
tissu
effici
mersrbdbas
subunit
vaccin
peptid
inhibitor
proven
use
mous
model
similarli
transgen
mice
develop
zhao
et
al
also
exhibit
high
viral
burden
viralposit
neuron
infect
merscov
system
inflamm
mildtosever
pneumonia
accompani
liver
kidney
spleen
injuri
also
observ
third
model
mous
gene
replac
human
ortholog
express
control
mous
regulatori
element
pascal
et
al
unlik
transgen
mice
express
whole
bodi
gener
agraw
et
al
result
mice
design
pascal
et
al
preserv
proper
express
regul
protein
tissu
distribut
infect
merscov
transgen
mice
resembl
human
patient
robust
viru
replic
lung
evid
interstiti
pneumonia
signific
lung
diseas
observ
indic
potenc
mous
model
studi
host
respons
merscov
effici
test
vaccin
drug
util
model
two
nab
show
except
potenc
inhibit
preand
postexpos
merscov
infect
two
speci
nhp
develop
merscov
infect
model
rhesu
macaqu
common
marmoset
merscovinfect
rhesu
macaqu
develop
mildtomoder
clinic
sign
within
h
includ
elev
bodi
temperatur
reduc
appetit
increas
respiratori
rate
cough
piloerect
hunch
postur
clinic
sign
transient
last
day
radiograph
chang
show
vari
degre
local
infiltr
interstiti
mark
none
anim
reach
clinic
score
requir
euthanasia
de
wit
et
al
munster
et
al
similar
symptom
infect
rhesu
macaqu
also
observ
anoth
independ
group
yao
et
al
use
anim
model
falzarano
et
al
evalu
effect
combin
treatment
ribavirin
use
treat
sar
patient
stockman
et
al
demonstr
antimerscov
effect
vitro
falzarano
et
al
interestingli
regimen
reduc
viru
replic
moder
host
respons
improv
clinic
outcom
infect
anim
falzarano
et
al
treatment
strategi
use
treatment
merscovposit
patient
patient
multipl
comorbid
diagnos
late
cours
ill
may
unfortun
benefit
strategi
altawfiq
et
al
common
marmoset
model
display
sever
clinic
diseas
rhesu
macaqu
initi
viral
load
lung
time
higher
rhesu
macaqu
lung
sever
marmoset
develop
sever
diseas
euthan
moreov
viral
replic
occur
lower
respiratori
tract
also
seen
rhesu
macaqu
detect
blood
nearli
test
tissu
associ
liver
andor
kidney
failur
indic
chang
blood
chemistri
taken
togeth
result
suggest
system
dissemin
infect
common
marmoset
therefor
rhesu
macaqu
appear
model
mildtomoder
transient
mer
case
wherea
marmoset
serv
sever
diseas
model
model
provid
import
insight
merscov
infect
mechan
host
immun
critic
antivir
therapeut
vaccin
evalu
conclus
spite
effort
mani
research
group
yet
licens
vaccin
therapeut
merscov
infect
due
suscept
viru
life
cycl
vaccin
target
either
full
length
truncat
protein
develop
among
dna
protein
candid
show
advanc
progress
protect
immun
mice
nhp
viru
challeng
merit
develop
candid
vaccin
merscov
potenti
human
applic
worth
note
asid
direct
human
protect
viru
infect
effect
dromedari
vaccin
also
need
stop
ongo
cameltohuman
transmiss
mva
dna
evok
nab
dromedari
regardless
although
merscov
infect
dromedari
may
show
sever
clinic
manifest
may
carri
merscov
viral
rna
nasal
excret
even
presenc
specif
antibodi
alagaili
et
al
hemida
et
al
khalafalla
et
al
mvamerss
vaccin
develop
haagman
et
al
evok
local
mucos
immun
respons
nostril
thu
reduc
viru
excret
merscov
infect
dromedari
may
therefor
promis
candid
vaccin
dromedari
applic
therapeut
target
also
develop
nab
inhibit
viral
entri
mainli
block
viru
attach
among
identifi
nab
two
display
efficaci
mice
exhibit
protect
preand
postchalleng
infect
mice
thu
deserv
evalu
nhp
model
although
escap
mutat
might
occur
select
nab
usag
nab
cocktail
target
differ
epitop
may
allevi
problem
moreov
peptid
inhibitor
design
base
fusion
core
structur
fortun
shown
benefit
postchalleng
infect
protect
enhanc
combin
interferon
b
assay
mice
channappanavar
et
al
also
merit
evalu
nhp
although
small
molecul
shown
antimerscov
potenti
vitro
vivo
efficaci
remain
unclear
evalu
efficaci
vaccin
therapeut
appropri
anim
model
need
among
develop
anim
model
mice
wide
use
due
low
cost
eas
use
evalu
common
marmoset
appear
repres
appropri
nhp
model
recapitul
sever
manifest
mer
patient
taken
togeth
current
advanc
develop
merscov
vaccin
therapeut
target
discuss
review
shown
import
implic
tackl
futur
cov
outbreak
